Overview of Endoscopy And Glp 1 Receptor Agonists

GLP‑1 receptor agonists increase retained gastric contents but do not significantly increase aspiration risk. Emerging evidence supports dietary modification over routine drug discontinuation before endoscopy . Risk-stratified peri-procedural assessment is more appropriate than universal GLP -1RA withholding. Gastric point-of-care ultrasound may aid decision-making in selected high-risk ...

AGA does not endorse all patients stopping GLP-1s prior to endoscopy , but rather an individualized approach to each patient.
Key Details About Endoscopy And Glp 1 Receptor Agonists

Background/Objectives: Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have transformed the management of type 2 diabetes mellitus and obesity. However, their sustained effect on delaying gastric emptying raises new challenges in gastrointestinal endoscopy performed under sedation. This narrative review aims to summarize current evidence on the impact of GLP-1 RAs on gastric motility and ...
Objective To assess whether use of glucagon-like peptide-1 ( GLP-1 ) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Design Cohort study. Setting Two deidentified US commercial healthcare databases. Participants 43 365 adults ...

Impact of GLP
Background Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) are commonly used to treat diabetes and obesity. Emerging evidence suggests that GLP-1 RAs may be linked to increased gastric residual content (GRC), aspiration pneumonia, and aborted esophagogastroduodenoscopy (EGD) procedures. Although a recent meta-analysis showed an increased risk of GRC and aborted EGDs with GLP-1 RA use, it ...
This review explores management of GLP-1 RAs in the periprocedural setting for endoscopic procedures based on current evidence and guidelines, highlighting gaps and future directions. Pharmacology and mechanisms of action GLP-1 RAs have several mechanisms of action that make them relevant in gastrointestinal endoscopy .

AGA Rapid Clinical Practice Update on the Management of Patients Taking ...
Clinical Dilemma There has been increasing concern about per- forming endoscopic procedures, in particular up-per endoscopies, on patients who are using glucagon-like peptide 1 ( GLP-1 ) receptor agonists ( GLP-1 RAs) because of their effect on slowing gastric motility and the risk of aspiration of retained gastric contents in sedated patients.
American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors

Increased Risk of Aspiration Pneumonia Associated With Endoscopic ...
Glucagon-like peptide 1 receptor agonists ( GLP -1RAs) are exciting new drugs in the management of diabetes and obesity; however, they are associated with delayed gastric and colonic transit times. The American Society of Anesthesiologists recently released a consensus-based guidance suggesting holding GLP -1RAs before an endoscopic or surgical procedure to decrease the risk of aspiration.1 ...






Glucagon-like Peptide-1 ( GLP-1 ) agonists cause delayed gastric emptying by acting on vagal afferent nerves. Retained gastric contents (RGC) increase the risk of pulmonary aspiration, particularly under anesthesia in endoscopic procedures. This ...